Actimed Therapeutics Appoints Martin Walton as Chief Financial Officer
Retrieved on:
Thursday, October 19, 2023
IND, AIM, Venture capital, Commercial bank, Cachexia, Toronto-Dominion Bank, Acquisition, Martin, NHS, Executive, Private equity, Association of British HealthTech Industries, LSE, CFO, Vulnerability and Risk Committee, Investment, Initial public offering, Liverpool Life Sciences UTC, Investigational New Drug, Wholesaling, Pharmaceutical industry, ActiMates
Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, today announces the appointment of Martin Walton as Chief Financial Officer.
Key Points:
- Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting disorders, today announces the appointment of Martin Walton as Chief Financial Officer.
- Since 2009, Martin has been an active Venture Capital and Private Equity investor, portfolio manager, and advisor in life sciences working with several of the largest investors in the sector.
- Robin Bhattacherjee, Actimed CEO, commented: “I am delighted to welcome Martin to Actimed, who brings with him a set of highly complementary skills and extensive industry experience.
- Martin Walton, Actimed CFO commented: “I am excited to be joining Actimed at this important point in the company’s journey to develop the first globally approved product for cancer cachexia.